Previous 10 | Next 10 |
BURLINGAME, Calif., May 17, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present new data for CPI-818, the Company’s ITK inhibitor, at the International Conference on Malignant Lymphoma (ICML)...
2023-05-12 16:25:30 ET Summary Additional Phase 1b data for CPI-818 in T cell lymphoma is expected in this quarter. Phase 2 data for Ciforadenant is expected this year. The stock's upside momentum is expected to continue over the next 1 year due to above catalysts. Corvu...
2023-05-10 12:34:48 ET Gainers: Unique Fabricating ( UFAB ) +132% . Harbor Custom Development HCDI +130% . CTI BioPharma CTIC +85% . Corvus Pharmaceuticals ( CRVS ) +57% . Microvast Holdings MVST +58% . Benson Hill BHIL +42% . Mi...
2023-05-08 22:24:08 ET Corvus Pharmaceuticals, Inc. (CRVS) Q1 2023 Earnings Conference Call May 08, 2023, 04:30 PM ET Company Participants Zack Kubow - IR-Real Chemistry Leiv Lea - CFO Richard Miller - CEO James Rosenbaum - SVP-Research Conference Call ...
2023-05-08 16:28:06 ET Corvus Pharmaceuticals press release ( NASDAQ: CRVS ): Q1 GAAP EPS of -$0.17 misses by $0.01 . For further details see: Corvus Pharmaceuticals GAAP EPS of -$0.17 misses by $0.01
Updated interim results from CPI-818 Phase 1/1b clinical trial continues to support potential of ITK inhibition and the ALC biomarker in T cell lymphoma Conference Call Today at 4:30 p.m. ET / 1:30 p.m. PT BURLINGAME, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals...
BURLINGAME, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and webcast on May 8, 2023 at 4:30 pm ET (1:30 pm PT) to provide a business update and repor...
Preclinical data supports targeting ITK as a new approach for cancer immunotherapy Novel mechanism of action modulates T cell differentiation and enhances the immune system via Th1 skewing, increased T cell cytolytic capacity and reduction of T cell exhaustion Enrollment continu...
2023-04-12 12:55:56 ET Gainers: National CineMedia ( NCMI ) +151% . TESSCO Technologies Incorporated ( TESS ) +87% . Guardforce AI ( GFAI ) +51% . Bullfrog AI Holdings ( BFRG ) +32% . Altamira Therapeutics ( CYTO ) +28% . Tri...
Interim data from Phase 1/1b clinical trial of CPI-818, including new evidence supporting the recently implemented minimum absolute lymphocyte count (ALC) predictive biomarker Data presented at the 10 th Whistler Global Summit on Hematologic Malignancies BURLINGAME, Ca...
News, Short Squeeze, Breakout and More Instantly...
Corvus Pharmaceuticals Inc. Company Name:
CRVS Stock Symbol:
NASDAQ Market:
Corvus Pharmaceuticals Inc. Website:
BURLINGAME, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that Richard A. Miller, M.D., president and chief executive officer, and Jeffrey Arcara, chief business officer, will conduct one-on-o...
Soquelitinib Phase 1 Randomized Trial in Atopic Dermatitis Enrolling at Multiple Centers; Potential for Early Data Before Year-End 2024 Soquelitinib Registration Phase 3 Trial in Peripheral T Cell Lymphoma Advancing Toward Initial Enrollment in Q3 2024 Interim Data from Ciforade...